Evidence map›Paper›PMID 41065979›Full record

ArticleApplied biochemistry and biotechnology2025

Pathway Reinforcement and Chassis Optimization of Escherichia coli BL21 for Enhancing Lacto‑N‑tetraose Production.

Xinyue Su, Yongzhong Wang, Qiang Ding

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xinyue SuSchool of Life Sciences, Anhui University, 230601, Hefei, China.
Yongzhong WangSchool of Life Sciences, Anhui University, 230601, Hefei, China. yzwang@ahu.edu.cn.
Qiang DingSchool of Life Sciences, Anhui University, 230601, Hefei, China. qiangd@ahu.edu.cn.

Funding

National Natural Science Foundation of China 22308002
6 · The paper itself

Abstract

Lacto‑N‑tetraose (LNT) is an important neutral non-fucosylated form of human milk oligosaccharides, widely recognized for its protective effects on infant health and enhancement of immune functions. In this study, to reinforce the fermentative synthesis of LNT, lactose utilization was enhanced for LNT production through overexpressing lacY (encoding the lactose permease gene) in Escherichia coli BL21, which can achieve the LNT titer and productivity of 1.55 g/L and 0.02 g/L/h, respectively. Moreover, the chassis was optimized through deleting byproduct genes: wecB (encoding UDP-N-acetyl glucosamine-2-epimerase), lacZ (encoding β-galactosidase), and the nagB gene (encoding glucosamine-6-phosphate deaminase), so we can obtain a 2.8 g/L LNT titer and 0.039 g/L/h productivity. Furthermore, we designed the UTP regeneration for precursor production through overexpressing the ndk gene (encoding nucleoside diphosphate kinase) and increased the LNT titer by 3.02 g/L. Finally, the LNT titer and productivity were improved to 3.22 g/L and 0.05 g/L/h by integrating the LgtA-WbgO expression cassette in the genome. This study establishes a stepwise optimization strategy in Escherichia coli BL21 for LNT biosynthesis, providing a foundation for industrial-scale production.

Indexed as

Escherichia coliLactoseMetabolic EngineeringOligosaccharidesEscherichia coli ProteinsFermentationEscherichia coli Proteinslacto-N-neotetraoseLactoseOligosaccharidesChassis optimizationEscherichia coli BL21FermentationLacto‑N‑tetraosePathway reinforcement

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.